IRMD
IRadimed Corporation
IRMD has slightly lower modeled downside risk, despite its lower overall score.
UNH
UnitedHealth Group Incorporated
UNH has a slight edge over IRMD overall, supported by stronger valuation.
IRMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
IRMD's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
IRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 32x | $59.44 | -30% |
| Forward | 36x | $85.23 | — |
| Fair | 41x | $76.32 | -10% |
| Current | 46x | $85.23 | — |
| Expensive | 71x | $133 | +57% |
Historical ranges are pointers, not guarantees.
IRMD has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
IRMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
IRMD has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
IRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.40 | +28% |
| Q3 2026 | $1.87 | +13% |
| Q2 2026 | $1.79 | +10% |
| Q1 2026 | $1.83 | +18% |
| Q4 2025 | $1.75 | +17% |
| Q3 2025 | $1.65 | +14% |
| Q2 2025 | $1.62 | +12% |
| Q1 2025 | $1.55 | +11% |
| Q4 2024 | $1.50 | +11% |
IRMD has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
IRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2M | +14% |
| Q2 2026 | $20.5M | +0.3% |
| Q1 2026 | $22M | +13% |
| Q4 2025 | $22.7M | +17% |
| Q3 2025 | $21.2M | +16% |
| Q2 2025 | $20.4M | +14% |
| Q1 2025 | $19.5M | +11% |
| Q4 2024 | $19.4M | +11% |
IRMD has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +1.4 points |
| Q2 2026 | 31% | -2 points |
| Q1 2026 | 33% | +5.1 points |
| Q4 2025 | 31% | +1.4 points |
| Q3 2025 | 32% | +0.6 points |
| Q2 2025 | 33% | +1.9 points |
| Q1 2025 | 28% | +0.9 points |
| Q4 2024 | 30% | +0.3 points |
IRMD has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
IRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.9M | +17% |
| Q2 2026 | $5.8M | +13% |
| Q1 2026 | $7.9M | +1226% |
| Q4 2025 | $5.6M | +76% |
| Q3 2025 | $5.8M | +10% |
| Q2 2025 | $5.1M | -7.2% |
| Q1 2025 | $594.6K | -84% |
| Q4 2024 | $3.2M | -5.4% |
IRMD generated $26M in free cash flow over the past year, up 77% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
IRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +4K shares |
| 1 year | +0.1% | +15.9K shares |
| 3 years | +1.1% | +140K shares |
| 5 years | +2.2% | +272K shares |
| Available history | +4.9% | +600K shares |
IRMD has 13M diluted shares, about the same as a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over IRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
IRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.2x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
IRMD has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
IRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 36.0 | Neutral |
IRMD's weekly RSI is 47 (neutral) and its Stochastic is 36 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
IRMD PE vs Healthcare Sector
| Metric | IRMD | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 76% above |
| PE % | 60 | 29 | 31 pts above |
IRMD is trading at 46x earnings, a 76% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over IRMD on valuation relative to its sector.
IRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.1 | 0.1% above |
| 20 week MA | $88.2 | 3.3% below |
| 50 week MA | $92.6 | 8% below |
| 100 week MA | $77.7 | 9.7% above |
| 200 week MA | $61.2 | 39% above |
IRMD's trend is mixed: it's above three of its five weekly moving averages, and 39% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over IRMD on trend strength, trading above more of its moving averages.
IRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.6 | $23.3 | -5.3% |
| 2021 | $23.3 | $45.9 | +97% |
| 2022 | $45.9 | $28.0 | -39% |
| 2023 | $28.0 | $47.5 | +70% |
| 2024 | $47.5 | $54.7 | +15% |
| 2025 | $54.7 | $97.5 | +78% |
| 2026 YTD | $97.5 | $85.2 | -13% |
IRMD has finished higher in four of the last six years, three of them by more than 50%. It's down 13% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over IRMD on returns for 2026, with the stronger performance.